Skip to main content

Table 1 Patient demography and treatment

From: Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis

Patient no. Diagnosis Treatment duration at second biopsy (months) Cumulative prednisolone dose at second biopsy (mg) Other immunosuppressive agents at second biopsy ANA (+/neg) and pattern Autoantibodies detected in line immunoassay
1 DM 8 6005 MTX +, granular neg
2 DM 5 5210 AZA +, granular neg
3 DM 7 7875 None +, granular neg
4 DMa 10 4778 MTX +, granular anti-Ro-52, anti-Ro-60, anti-LA
5 DM 11 7179 AZA +, granular neg
6 DM 9 8668 AZA neg anti-Ro-52
7 DMb 4 3935 None +, granular anti-Ro-52, anti-PL7
8 DMb 8 NA AZA, CsA +, granular anti-Ro-52
9 PM 6 5250 MTX +, granular and homogenous anti-Ro-52, anti-SRP
10 PM 12 9090 AZA +, granular neg
11 PM 11 9013 MTX, AZA NA NA
12 PMb 16 6775 AZA neg anti-Mi2
13 PMb 4 5525 CYC neg anti-Jo-1, anti-Ro-52
14 PMb 6 1360 None neg neg
15 PM 9 3702 AZA neg anti-Ro-52, anti-Ro-60
16 PM 8 8435 AZA +, granular anti-Ro-52
  1. aAdditional diagnosis Sjögren's syndrome.
  2. bDiagnosis probable
  3. + positive, ANA anti-nuclear antibodies, AZA azathioprine, CsA cyclosporine A, CYC cyclophosphamide, DM dermatomyositis, MTX methotrexate, NA not available, neg negative, PM polymyositis